Global Fund and US expand access to HIV prevention drug lenacapavir

The Global Fund and the US are expanding access to Gilead's HIV prevention drug, aiming to reach 3 million people by 2028. Initial shipments of lenacapavir, a twice-yearly injection, have arrived in nine African nations. The program will extend to twelve more countries, including the Dominican Republic and Thailand. This initiative addresses challenges with daily oral PrEP, with strong uptake among key populations like pregnant women and young women. Gilead has licensed generic production to broaden availability.